Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$20.04 USD
+0.21 (1.06%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $20.14 +0.10 (0.50%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Jasper Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 87 | 38 | 85 | 1 | 1 |
Receivables | 0 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 3 | 0 | 0 |
Total Current Assets | 89 | 42 | 88 | 1 | 2 |
Net Property & Equipment | 3 | 4 | 4 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 100 | 100 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 1 | 0 | 0 |
Total Assets | 95 | 48 | 94 | 101 | 102 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 4 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 4 | 4 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 7 | 8 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 3 | 14 | 96 | 97 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 12 | 24 | 96 | 97 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 248 | 141 | 137 | 6 | 5 |
Retained Earnings | -170 | -105 | -67 | -1 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 78 | 36 | 70 | 5 | 5 |
Total Liabilities & Shareholder's Equity | 95 | 48 | 94 | 101 | 102 |
Total Common Equity | 78 | 36 | 70 | 5 | 5 |
Shares Outstanding | 11.10 | 3.80 | 3.70 | 1.20 | 0.30 |
Book Value Per Share | 7.07 | 9.47 | 18.79 | 4.17 | 16.67 |
Fiscal Year End for Jasper Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 107 | 118 | 87 | 104 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 2 | 2 | 1 |
Total Current Assets | NA | 109 | 120 | 89 | 105 |
Net Property & Equipment | NA | 2 | 2 | 3 | 3 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 1 |
Total Assets | NA | 114 | 126 | 95 | 110 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 6 | 6 | 7 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 10 | 9 | 12 | 12 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 14 | 13 | 16 | 16 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 298 | 297 | 248 | 247 |
Retained Earnings | NA | -198 | -183 | -170 | -153 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 100 | 113 | 78 | 94 |
Total Liabilities & Shareholder's Equity | NA | 114 | 126 | 95 | 110 |
Total Common Equity | 0 | 100 | 113 | 78 | 94 |
Shares Outstanding | 15.10 | 15.10 | 15.00 | 11.10 | 11.00 |
Book Value Per Share | 0.00 | 6.64 | 7.55 | 7.07 | 8.56 |